Effect of Azadirachta indica leaf extract on carbontetrachloride-induced hepatic damage in albino rats

A. M. MUJUMDAR*, ANURADHA S. UPADHYE AND A.M. PRADHAN¹
*Agharkar Research Institute, Agarkar Road, Pune 411 004.
¹K.E.M. Hospital, Rasta Peth, Pune 411 011.

The shade dried leaves of Azadirachta indica were extracted successively by petroleum ether (60-80°) and ethanol. The ethanol extract after removal of solvent was studied for carbontetrachloride induced hepatic changes using 0.5 g and 1 g/kg oral dose in albino rats. The changes were assessed by serum enzyme profile that include glutamic oxaloacetate transaminase (GOT), glutamic pyruvic transaminase (GPT), alkaline phosphatase (AP), bilirubin (B) and hepatic triglycerides (HTG) levels, histological changes in liver and pentobarbitone sleeping time as a functional parameter. There was significant reversal of biochemical, histological and functional changes induced by carbontetrachloride in rats by ethanol extract treatment.

ZADIRACHTA indica A. Juss (Neem) of family Meliaceae is native to Indian sub-continent. Now $oldsymbol{\lambda}$ a-days it is grown in many Asian countries and tropical region of the Western hemisphere. Since ancient times, seeds and leaves of this tree have been used traditionally to cure various human ailments and as a household pesticide1. Different parts of this plant have been reported to possess various medicinal properties^{2,3}. Leaves of this plant are traditionally known or reported for various biological activities like antiinflammatory4, anxiolytic5, antiandrogenic⁶, antistress⁷, humoral and cell mediated immunostimulant⁸, anithyperglycmic⁹, liver stimulant^{10,11} antiviral¹² and antimalarial¹³. Traditionally decoction of leaves of this plant is used for jaundice and liver complaints in Sagar district of Madhya Pradesh¹⁴. In view of this, it was proposed to screen leaf extract on carbontetrachloride(CCI₄) induced hepatotoxicity in rats. CCI, is well known liver toxin and it causes structural, functional and compositional changes in liver¹⁵.

MATERIALS AND METHODS

Plant material: The leaves of A. indica were collected

*For Correspondence

from Pune region in bulk quantity and shade dried. These dried leaves were coarsely powdered and defatted using petroleum ether (60-80°), subsequently extracted exhaustively in a soxhlet apparatus with ethanol. This extract (ET) was dried at low temperature and pressure (yield 6.99%). It showed presence of flavonoids, saponins, tannins in preliminary phytochemical tests.

Albino rats (HA strain) of either sex weighing between 80-120 g were obtained from the animal colony of Agharkar Research Institute (ARI) for experimental purpose. They were housed in an air-conditioned area at 25±2° with 10:14 hours light and dark cycle. The animals were maintained on Amrut brand pellet feed and water ad libitum. They were kept fasting 24 hours prior to experimentation.

ET was administered orally upto 2 g/kg to individual rat in a group. There was no mortality due to the above treatment. Hence, for further studies 1 g/kg per oral maximum dose was employed.

Initial pilot studies were performed using various doses of CCI₄ as well as extract using three rats per dose at various time intervals. The criteria for the selection of dose and the time interval for hepatotoxicity and reversal of

Table No. 1: Effect of ET on pentobarbitone sleeping time in albino rats

Group No.	Treatment	Mean sleeping time in minutes ± SE. 37.00 ± 3.44		
1	Control			
2	CCI ₄	73.25 ± 4.19*		
3	ET-0.5 g/kg	42.00 ± 3.46**		
4	ET-1 g/kg	42.25 ± 3.74**		
5	CCI₄+ET-0.5 g/kg	62.75 ± 4.47 @ @		
6	CCI ₄ +ET-1 g/kg	56.00 ± 2.02 @		

- 1. * Significant, ** Non-significant as compared to control.
- 2. @ Significant, @ @ Non-significant as compared to CCI₄ treatment group only.

hepatotoxicity by CCI₄ with extract respectively were functional, biochemical and histopathological changes induced by CCI₄ in rats.

Effect on pentobarbitone-sleeping time in albino rats:

Pentobarbitone was administered in a dose of 35 mg/kg by intraperitoneal route to albino rats for this study. Time interval between loss and regain of righting reflex was measured as sleeping time. A group of 48 rats was divided randomly in 6 groups of 8 rats each. The effect of oral dose of ET 0.5 g and 1 g/Kg was studied 24 hours after subcutaneous treatment of 1.50 ml/kg CCl₄ in olive oil (1:1) to assess effect on pentobarbitone-induced hypnosis using corresponding control as shown in Table No. 1.

Effect on CCI₄ induced hepatotoxicity: In this study CCI₄ in a dose of 2 ml/kg in olive oil (1:1) was administered subcutaneously as hepatotoxic agent. A group of 36 rats was divided randomly into 6 groups of 6 each. The treatment of ET was given in a dose of 0.5 g and 1 g/kg by oral route for 8 days. Subsequently, after 8th day treatment, blood from each rat was collected through cardiac puncture under ether anaesthesia. The serum was separated for estimating the following; glutamic oxaloacetic transaminase (GOT), glutamic pyruvic transaminase (GPT)¹⁶, alkaline phosphatase (AP)¹⁷, bilirubin (B)¹⁸ and hepatic triglyceride (HTG)¹⁹ was estimated from 1 g liver homogenate in 10 ml normal saline.

The liver from each animal was removed after dissection. The liver lobes were fixed for 48 hours in 10% formalin and were embedded in paraffin. Subsequently, 5 μ sections were cut on a microtome and stained with haematoxylin and eosin. These sections were observed under light microscope for histological changes and compared to normal liver histology.


Statistical analysis: All results of pentobarbitone sleeping time and biochemical estimations were reported as mean ± SE. These studies were further analysed by using students t test to calculate significance of the results. The p values greater than 0.05 were considered as non-significant.

RESULTS

Effect on pentobarbitone-sleeping time: The effect of 0.5 g and 1 g per kg of ET by oral route was studied on pentobarbitone sleeping time, with CCl₄ and without CCl₄ pretreatment. The results are shown in table No. 1. There is no significant effect on sleeping time due to ET pretreatment prior to pentobarbitone. Further there is dosedependent reduction in sleeping time due to ET treatment in CCl₄ pretreated rats. However, this value is significant at higher dose only.

Effect on CCI₄ induced hepatotoxicity in rats -The effect of ET treatment on normal and CCI₄ pre-treated rats for 8 days on various biochemical parameters are shown in table No. 2. There is no alteration in the biochemical profile studied in control and ET treated rats. As shown in table No. 2 there is significant alteration in all biochemical parameters due to CCI₄ treatment only. There is reduction in all biochemical parameters in CCI₄ pretreated groups due to ET treatment. However, these values are significant at 1 g/kg dose of ET only.

The histopathological profile of liver of CCI₄ treated rats is shown in plate which showed intense characteristic centrilobular necrosis and vacuolization with fatty degeneration. There was scanty mononuclear infiltration in the area of fatty degeneration. However, the extract treated animals which are pretreated with CCI₄, showed focal microvesicular fatty degeneration, with mononuclear cell infiltration and focal spotty necrosis. Thus, extent of damage caused by CCI₄ is reduced due to ET treatment. The hepatic cells are not altered by ET treatment alone.



Effect of ET treatment on CCI4 induced hepatic histopathological changes in albino rats

- (A) Control, (B) ET 1 g/kg treatment, (C) CCI, induced hepatic changes,
- (D) Reversal of CCI, induced hepatic changes by ET-1 g/kg treatment

DISCUSSION

Liver is a versatile organ in the body concerned with regulation of internal chemical environment. Therefore, damage to the liver inflicted by hepatotoxic agents is of grave consequence. There is an ever increasing need for an agent which could protect liver from damage, especially of one which facilitates regeneration by proliferation of parenchymal cells after damage and arrest growth of fibrous tissue²⁰. As such liver is highly affected primarily by toxic agents such as CCl₄, paracetamol, D-galactosamine, alcohol and thioacetamide through different mechanisms²¹.

In the present study, CCI₄ is used as a hepatotoxic agent. It is well established that hepatotoxicity by CCI₄ is due to enzymatic activation to release CCI₃ radical in free state, which in turn disrupts the structure and function of lipid and protein macromolecules in the membrane of the

cell organelles^{22,23}. After treatment with CCI₄ there is significant rise in serum GOT, GPT, bilirubin and alkaline phosphatase levels as compared to control animals. This enzyme profile is altered in dose dependant manner due to ET treatment, however, it is significantly lowered only at 1 g/kg dose. This finding is further supported by histopathological observations. These observations are in corroboration with the earlier work carried out by Chattopadhyay et al11 using paracetamol as hepatotoxicant. It is known that CCI, enhances lipid peroxidation leading to accumulation of triglycerides in hepatic parenchyma cells24,25 a step further leads to necrosis26. In the present study, hepatic triglyceride levels are significantly reduced in CCI, pre-treated animals due to ET treatment. Effect on pentobarbitone sleeping time is taken as a functional index for the microsomal enzyme activity. The ET has shown reduction in sleeping time and shown protection against CCI, induced potentiation of sleeping time. Thus, all these

Table No. 2

Effect of ET treatment on various biochemical parameters in CCI₄ pre-treated rats

Grou	up Treatment	Va	Various biochemical parameters ± SE			
No.		GOT (U)	GPT (U)	B (mg/l)	AP (U)	HTG (mg/g wet wt)
1.	Control	74.99	51.63	2.65	78.48	16.62
••	30	± 4.93	± 2.81	± 0.11	± 2.42	± 0.84
2.	CCI ₄	99.11* ± 4.95	69.29* ± 3.11	12.87* ± 0.51	106.59* ± 2.71	38.70* ± 2.97
3.	ET-0.5 g/kg	69.05** ± 2.07	50.28** ± 2.55	2.76** ± 0.16	78.89** ± 1.85	14.91** ± 0.83
4.	ET-1 g/kg	75.34** ± 2.18	46.40** ± 1.97	2.91** ·± 0.20	80.22** ± 1.51	13.59** ± 0.45
5.	CCI ₄ + ET 0.5 g/kg	91.57@@ ± 2.60	63.40@@ ± 3.10	11.84@@ ± 0.31	102.75@@ ± 3.60	35.85@@ ± 2.19
6.	CCI ₄ +ET 1 g/kg	83.34@ ± 4.70	60.28@ ± 2.56	8.76@ ± 0.45	88.34@ ± 2.14	28.12@ ± 1.72

^{*} Significant, ** Non-significant as compared to control.

findings together conclude that ET has biochemical, histopathological and functional protection against CCI₄-induced hepatic damage.

ACKNOWLEDGEMENTS

Authors are grateful to Dr. (Mrs.) Chiplonkar from ARI for her help in statistical analysis of the results. AMM and ASU are thankful to Dr. M.S. Kumbhojkar, In-Charge, Botany Group and Dr. A.D. Agate, Director, ARI for providing necessary facilities for this work.

REFERENCES

- 1. Kaul, O., Isman, M. B. and Ketkar, C. M., Can. J. Bot., 1990, 68, 1.
- 2. Chopra, R. N., Nayer, S. L. and Chopra, I. C., In:

- Glossary of Indian Medicinal Plants, CSIR, New Delhi 1956, 31.
- 3. Kirtikar, K. R. and Basu, B. D., In: Indian Medicinal Plants, L. M. Basu, Allahabad 1933, 1, 536.
- 4. Chattopadhyay, R. R., Chattopadhyay, R. N. and Maitra, S. K., Indian J. Pharmacol. 1993, 25, 99.
- 5. Jaiswal, A. K., Bhattacharya, S. K. and Acharya, S.B., Indian J. Expt. Biol., 1994, 32, 489.
- Kasturi, M., Manirannan, B., Ahamed, R.N., Shaikh, P. D. and Pathan, K. M., Indian J. Expt. Biol., 1995, 33, 725.
- Sen, P., Medinata, P. K. and Ray, A., Indian J. Expt. Biol., 1992, 30, 1170.
- 8. Ray, A., Banerjee, B.D. and Sen, P., Indian J. Expt. Biol., 1996, 34, 698.
- 9. Chattopadhyay, R. R., Chattopadhyay, R.N., Nandy, A. K., Poddar, G. and Maitra, S.K., Bull. Calcutta Sch. Trop. Med., 1987, 35, 29.
- 10. Desai, V.G., Aushadhi Sangrah, Gajanan Book Depot,

[@] Significant, @ @ Non-significant as compared to CCI, treatment only.

- Bombay, 1975, 166.
- 11. Chattopadhyay, R. R., Sarkar, S. K., Ganguly, S., Banerjee, R. N., Basu, T. K., and Mukherjee, A., Indian J. Expt. Biol., 1992, 30, 738.
- Gagati, S. S. and Marathe, A. D., J. Res. Edu. Indian Med., 1989, 8, 1.
- 13. Khalid, S. A., Dudck, H. and Gonzale, S. M., J. Nat. Product, 1989, 52, 922.
- 14. Bhalla, N.P., Sahu T.R., Mishra, G.P. and Dakwale, R.N. J. Econ. Tax. Bot., 1992, 3, 23.
- 15. Recknagal, R.O. Pharmacol. Rev., 1967, 19, 145.
- Bergmeyer, H.V. and Horder, M.,. Clin. Chim. Acta, 1980, 105, 147F.
- Bessey, D. A., Lowry, O.H. and Brock, M.J., J. Bio. Chem., 1946, 164, 321.

- 18. Jendrassik, L. and Grof, P., Biochem Z, 1938, 297, 81.
- 19. Bucolo, G. and David, M., Clin. Chem, 1973, 19, 76.
- 20. Rege, N., Dahanukar, S. and Karandikar, S. M., Indian Drugs, 1984, 21, 544.
- Doreswamy, R. and Sharma, D., Indian Drugs, 1995, 32, 139.
- 22. Slater, T. F., Nature, 1966, 209, 36.
- 23. Recknagei, R. O. and Glende, F. A., CRC Crit Rev Toxicol., 1973, 2, 263.
- 24. Reynolds, E. S. and Moslen, M. T. In: Toxic injury of the liver, Faber, F. and Fisher, M. M. Eds, Marcel Dekker Inc New York, 1980, 541.
- 25. Schotz, M. C., Baker, N. and Chavez, M. N. J. Lipid Research, 1964, 5, 569.
- 26. Chauhan, C. K., Nanivadekar, S. A. and Billimoria, F. R. Indian J. Pharmacol., 1992, 24, 107.